#NIAID

Highlights from the research presented at the 9th International AIDS Society Conference on HIV Science in Paris.

The vaccine prompted a robust immune response against HIV in those without the virus; now researchers hope to move it into advanced trials.

HIV prevention efforts would also take a huge hit under Trump’s draconian proposed budget cuts and the House health care bill.

With a major new HIV vaccine trial under way, cautious optimism is stirring that the vaccine will prove effective enough for a rollout.

The goal is to manufacture HIV envelope protein immunogens that prevent HIV infection.

How long did it take to develop other vaccines? Check out this AVAC chart.

Recipients Anthony Fauci oversees “critical” research in the United States and Frank Plummer did “groundbreaking” work in Africa.

NIAID research will build on the ASPIRE trials. Those findings showed that dapivirine rings provided “modest” HIV protection.

For the first time, a major clinical trial has found that starting antiretroviral treatment soon after HIV diagnosis reduces the risk of sickn...

Monday, May 18, is HIV Vaccine Awareness Day (HVA), a time to educate about the importance of a vaccine and to thank those working to find an...

Two Duke research teams received multiyear grants from NIAID totaling $20 million for work on HIV vaccines.

New research has shown that broadly neutralizing antibodies can block HIV from entering into or replicating inside of CD4 cells in a laborator...

Researchers have mapped the development of a key HIV antibody, establishing scientific knowhow that may aid in the development of a vaccine.

The new awards expand research beyond HIV/AIDS to include tuberculosis and hepatitis.

How pharmaceutical and biotech companies are playing a major role in the search for an HIV cure.

Researchers have made the long-elusive discovery of the precise mechanism HIV uses to kill human immune cells.